Medifast, Inc. filings document the public-company disclosures of a NYSE-listed metabolic health and wellness business centered on its coach-guided lifestyle system. Form 8-K reports furnish quarterly and annual earnings releases that detail revenue, gross profit, active earning coach trends, liquidity, debt status and management commentary on the company's metabolic health strategy.
Proxy and current reports cover board elections, stockholder voting results, executive compensation, equity incentive plan amendments, leadership changes and material definitive agreements. Recent governance disclosures include a stockholder cooperation agreement, annual meeting matters and compensatory arrangements connected to executive transitions.
Medifast (MED) reported a weak quarter as demand softened. Revenue was $89.4 million, down 36.2% year over year, and the company posted a net loss of $2.3 million ($0.21 per diluted share) versus a profit a year ago. Nine‑month revenue was $310.7 million, down 35.7%, with a net loss of $0.6 million.
Results reflect a sharp decline in the OPTAVIA coach network and productivity. Active earning coaches fell to 19,500 from 30,000, and average revenue per active coach slipped to $4,585. Gross margin narrowed to 69.5% (down 590 bps), pressured by lower volume leverage and a reserve tied to reformulating the Essential product line. SG&A fell in dollars but remained elevated at 74.1% of revenue.
Liquidity remains solid: cash, cash equivalents and investments were $173.5 million, with working capital of $161.1 million. Operating cash flow was $12.1 million for the nine months. The company exited its LifeMD equity position earlier in the year, contributing to $7.2 million of other income year‑to‑date. Shares outstanding were 10,991,273 as of October 27, 2025.
Medifast, Inc. (MED) reported an administrative update via Form 8-K. The company announced it issued a press release covering earnings for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, meaning it is not subject to Section 18 of the Exchange Act and will not be incorporated into other filings unless specifically referenced. No financial figures are included in this notice; detailed results are contained in the attached press release.
Medifast Schedule 13G filing summary The reporting entities—G1 Execution Services, LLC; Susquehanna Fundamental Investments, LLC; and Susquehanna Securities, LLC—report aggregate beneficial ownership of 785,606 shares, representing 7.2% of Medifast's outstanding common stock based on 10,938,000 shares outstanding as of June 30, 2025. The filing expressly states that the Susquehanna Securities total includes options to acquire 695,200 shares.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control. The report is executed and signed on August 13, 2025. No additional transactions, plans, or intentions are disclosed in this statement.
Medifast Director Xian Ming received two grants of Restricted Stock Units (RSUs) on June 25, 2025:
- 11,167.65 cash-settled RSUs as part of director compensation, vesting fully on June 25, 2026
- 6,013.35 additional RSUs valued at $13.39 per share (based on 20-day moving average), elected in lieu of cash compensation
Both RSU grants will be payable in cash upon Ming's termination of service as director. Following these transactions, Ming beneficially owns 26,129.568 RSUs from the first grant and 32,142.918 RSUs from the second grant. The RSUs were granted under Medifast's Director's Deferred Compensation Plan and the Amended and Restated 2012 Share Incentive Plan.
Medifast Director Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and represent the right to receive an equivalent number of common shares.
Key details of the transaction:
- The RSUs will fully vest on June 25, 2026
- Shares are granted under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Schlackman owns 25,548.707 shares directly
- The grant is part of annual director compensation
The Form 4 was filed through an attorney-in-fact, Jason L. Groves, on June 26, 2025, within the required reporting timeline for insider transactions.
Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.
Key details of the transaction:
- RSUs were granted at $0 cost to the director
- Each unit represents one share of Medifast common stock
- Full vesting scheduled for June 25, 2026
- Following the transaction, Thomas owns 24,017.123 shares directly
This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.
Director Michael A. Hoer of Medifast received a significant equity grant of 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details of the transaction:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Hoer owns 26,139.473 shares directly
- The RSUs were granted in connection with annual director compensation
This Form 4 filing, signed by attorney-in-fact Jason L. Groves, indicates continued alignment of director interests with shareholders through equity-based compensation.